We immortalized rat T cells with helper-inducer phenotype, by HTLV-I superinfection. These immortalized cells had integrated human T-cell lymphotropic virus (HTLV)-I provirus genomes and showed nuclear polymorphism resembling adult T-cell leukemia cells. Among HTLV-I carrier rats of several strains, only WKAH strain rats developed a chronic progressive myeloneuropathy with spastic paraparesis of the hind limbs (HAM rat disease), after a long incubation period. Clinical and neuropathological features of HAM rat disease generally mimic those of HAM/TSP in humans, although T-cell infiltration is absent in the affected spinal cord lesions in the case of HAM rat disease. The collective evidence suggests that the major pathogenetic pathway of HAM rat disease appears to be closely related to apoptotic death of myelin-forming cells, oligodendrocytes and Schwann cells. Putative factors involved in apoptosis of these cells are discussed in relation to HTLV-I infection.

Keywords:
HTLV-I, Rat model, HAM/TSP, Oligodendrocytes, Apoptosis
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.